LYT-200 + tislelizumab

LYT-200 + tislelizumab is a **combination therapy** under clinical investigation for advanced and relapsed/refractory solid tumors, notably head and neck cancers. LYT-200 is a **first-in-class monoclonal antibody targeting galectin-9**, a protein implicated in cancer cell proliferation and immune suppression. By blocking galectin-9, LYT-200 reactivates intratumoral T cells, prevents galectin-9–induced cytotoxic T cell apoptosis, and inhibits immunosuppressive M2 macrophage activity[1][2][3]. Tislelizumab is an **anti–PD-1 monoclonal antibody** (also known as Tevimbra) that blocks the programmed cell death protein 1 (PD-1), thus relieving inhibition on immune cells and enhancing anti-tumor immune responses[3][4]. Preclinical evidence indicates that LYT-200 synergizes with anti–PD-1 agents in vivo, increasing CD4 and CD8 T cell activation and cytotoxicity in tumor models[1][3]. The combination has shown **durable responses and disease control in phase 1/2 trials in recurrent/metastatic head and neck cancers**. LYT-200 is developed by PureTech and its oncology entity, Gallop Oncology; tislelizumab is developed by BeiGene[2][3][4]. Primary indications under investigation are **head and neck cancers, urothelial cancer, and other locally advanced/metastatic solid tumors**[1][2][3][4].

Other names

galectin-9 antibody + anti–PD-1 antibodyLYT-200 + Tevimbra